Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies

​

Eli Lilly and Company has reported findings from an indirect treatment comparison analysing data from the ACHIEVE-3 and PIONEER PLUS studies of its investigational therapy Foundayo against oral semaglutide in adults with type 2 diabetes.

The post Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies appeared first on Hospital Management.

 

Back to the Featured Stories
Lilly reports comparative data from ACHIEVE-3 and PIONEER PLUS studies

Featured Stories

Cambridge Heartwear receives $243m tender for HeartSense wearable
Viking Therapeutics begins study of oral VK2735 for obesity
Gilead Sciences signs five-year DevOps agreement with Cognizant
FDA clears Abbott’s CardioMEMS HF system updates
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us